A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.
A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.
复制标题
DOI：
10.1002/ijc.27608
复制
发表时间：
2013-01-01
影响因子：
6.4
通讯作者：
Castle, Philip E.
中科院分区：
文献类型：
--
作者：
Wheeler, Cosette M.;Hunt, William C.;Cuzick, Jack;Langsfeld, Erika;Pearse, Amanda;Montoya, George D.;Robertson, Michael;Shearman, Catherine A.;Castle, Philip E.
目前，两种针对 HPV 16 和 18 的预防性人乳头瘤病毒 (HPV) 疫苗已被证明对于预防前驱病变非常有效，尽管这些疫苗在现实世界临床环境中的有效性仍需确定。为此，新墨西哥州建立了一项持续的全州范围监测计划，以评估宫颈癌预防护理的各个方面。鉴于宫颈癌发病率的下降预计需要几十年才能显现出来，在广泛接种 HPV 疫苗之前，采用了 47,617 名参加宫颈筛查的女性的年龄和细胞学分层样本，对 HPV 类型特异性患病率进行了系统性的人群测量。使用针对 37 种 HPV 基因型的经过充分验证的 PCR 方法来测试液基细胞学标本。 37 种 HPV 类型中任何一种的患病率总体为 27.3%，20 岁时最高为 52%，随后在年龄较大时迅速下降。年龄≤20岁、21-29岁或≥30岁女性的HPV 16患病率分别为9.6%、6.5%和1.8%。这些年龄组中 HPV 16 和 18 的综合患病率分别为 12.0%、8.3% 和 2.4%。在 54.5% 的高度鳞状上皮内（细胞学）病变 (HSIL) 和 25.0% 的低度 SIL (LSIL) 病变中检测到 HPV 16 和/或 HPV 18。这些基线数据能够估计 HPV 疫苗随时间的最大影响，并提供对于评估 HPV 疫苗接种的临床益处和潜在危害（包括非疫苗 HPV 类型的增加（即类型替代））非常重要的关键参考测量。
Currently, two prophylactic human papillomavirus (HPV) vaccines targeting HPV 16 and 18 have been shown to be highly efficacious for preventing precursor lesions, although the effectiveness of these vaccines in real world clinical settings must still be determined. Toward this end, an ongoing statewide surveillance program was established in New Mexico to assess all aspects of cervical cancer preventive care. Given that the reduction in cervical cancer incidence is expected to take several decades to manifest, a systematic population-based measurement of HPV type-specific prevalence employing an age- and cytology-stratified sample of 47,617 women attending for cervical screening was conducted prior to widespread HPV vaccination. A well-validated PCR method for 37 HPV genotypes was used to test liquid-based cytology specimens. The prevalence for any of the 37 HPV types was 27.3% overall with a maximum of 52% at age 20 years followed by a rapid decline at older ages. The HPV 16 prevalence in women aged ≤ 20 years, 21-29 years, or ≥ 30 years was 9.6%, 6.5%, and 1.8%, respectively. The combined prevalence of HPV 16 and 18 in these age groups was 12.0%, 8.3% and 2.4%, respectively. HPV 16 and/or HPV 18 were detected in 54.5% of high-grade squamous intraepithelial (cytologic) lesions (HSIL) and in 25.0% of those with low-grade SIL (LSIL). These baseline data enable estimates of maximum HPV vaccine impact across time and provide critical reference measurements important to assessing clinical benefits and potential harms of HPV vaccination including increases in non-vaccine HPV types (i.e., type replacement).
登录
查看更多内容
影响因子：
51.1
作者：
de Sanjose, Silvia;Quint, Wim G. V.;Xavier Bosch, F.
通讯作者：
Xavier Bosch, F.
影响因子：
168.9
作者：
Bulkmans, N. W. J.;Berkhof, J.;Meijer, C. J. L. M.
通讯作者：
Meijer, C. J. L. M.
影响因子：
6.4
作者：
Kjaer, Susanne K.;Breugelmans, Gabrielle;Iftner, Thomas
通讯作者：
Iftner, Thomas
影响因子：
3.8
作者：
Insinga, Ralph P.;Perez, Gonzalo;Haupt, Richard M.
通讯作者：
Haupt, Richard M.
影响因子：
56.3
作者：
Donovan, Basil;Franklin, Neil;Fairley, Christopher K.
通讯作者：
Fairley, Christopher K.